Trinity Biotech Provides an Update on the Continued Development of Its Continuous Glucose Monitor Technology
September 09, 2024 16:05 ET
|
Trinity Biotech plc
DUBLIN, Ireland, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions,...
BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
September 09, 2024 16:05 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
Mission Produce™ Announces Fiscal 2024 Third Quarter Financial Results
September 09, 2024 16:05 ET
|
Mission Produce, Inc.
Year-to-date momentum continues with ongoing strength of the Marketing & Distribution segment Operating cash flow for the first nine months of fiscal 2024 increased by $62.7 million versus the...
Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024
September 09, 2024 16:05 ET
|
Pulmonx Corporation
CONVERT trial data demonstrate AeriSeal® System is safe and effective with 77.6% of patients converted from CV+ to CV- 5-year durability data from LIBERATE study demonstrate positive, durable...
IZEA Appoints Digital Leader Patrick Venetucci as Chief Executive Officer
September 09, 2024 16:05 ET
|
IZEA Worldwide, Inc.
ORLANDO, Fla., Sept. 09, 2024 (GLOBE NEWSWIRE) -- IZEA Worldwide, Inc. (NASDAQ: IZEA), a leading provider of influencer marketing technology today announced the appointment of Patrick Venetucci as...
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
September 09, 2024 16:05 ET
|
Aprea Therapeutics
DOYLESTOWN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology...
Abivax presents first-half 2024 financial results
September 09, 2024 16:01 ET
|
Abivax
Abivax presents first-half 2024 financial results Cash balance of EUR 222M at June 30, 2024; cash runway in to Q4 2025 PARIS, France, September 9, 2024, 10:00 p.m. CEST – Abivax SA...
Terns Announces Proposed Public Offering
September 09, 2024 16:01 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
September 09, 2024 16:00 ET
|
Pacira BioSciences
TAMPA, Fla., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today...
Valley National Bancorp to Announce Third Quarter 2024 Earnings
September 09, 2024 15:23 ET
|
Valley National Bank
NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Valley National Bancorp (NASDAQ:VLY), the holding company for Valley National Bank, announced that it will release its third quarter 2024 earnings before...